AU2013276565B2 - Tailored liposomes for the treatment of bacterial infections - Google Patents

Tailored liposomes for the treatment of bacterial infections Download PDF

Info

Publication number
AU2013276565B2
AU2013276565B2 AU2013276565A AU2013276565A AU2013276565B2 AU 2013276565 B2 AU2013276565 B2 AU 2013276565B2 AU 2013276565 A AU2013276565 A AU 2013276565A AU 2013276565 A AU2013276565 A AU 2013276565A AU 2013276565 B2 AU2013276565 B2 AU 2013276565B2
Authority
AU
Australia
Prior art keywords
empty liposomes
liposomes
sphingomyelin
cholesterol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013276565A
Other languages
English (en)
Other versions
AU2013276565A1 (en
Inventor
Eduard Babiychuk
Annette Draeger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bern
Original Assignee
University of Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bern filed Critical University of Bern
Publication of AU2013276565A1 publication Critical patent/AU2013276565A1/en
Application granted granted Critical
Publication of AU2013276565B2 publication Critical patent/AU2013276565B2/en
Priority to AU2019201776A priority Critical patent/AU2019201776B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AU2013276565A 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections Active AU2013276565B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019201776A AU2019201776B2 (en) 2012-06-14 2019-03-14 Tailored liposomes for the treatment of bacterial infections

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12171924.9 2012-06-14
EP12171924 2012-06-14
EP13153039.6 2013-01-29
EP13153039 2013-01-29
PCT/EP2013/062207 WO2013186286A1 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201776A Division AU2019201776B2 (en) 2012-06-14 2019-03-14 Tailored liposomes for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
AU2013276565A1 AU2013276565A1 (en) 2014-12-18
AU2013276565B2 true AU2013276565B2 (en) 2018-12-20

Family

ID=48703423

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013276565A Active AU2013276565B2 (en) 2012-06-14 2013-06-13 Tailored liposomes for the treatment of bacterial infections
AU2019201776A Active AU2019201776B2 (en) 2012-06-14 2019-03-14 Tailored liposomes for the treatment of bacterial infections

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019201776A Active AU2019201776B2 (en) 2012-06-14 2019-03-14 Tailored liposomes for the treatment of bacterial infections

Country Status (19)

Country Link
US (4) US10744089B2 (enExample)
EP (2) EP2861214B1 (enExample)
JP (2) JP6382801B2 (enExample)
CN (2) CN104602672B (enExample)
AU (2) AU2013276565B2 (enExample)
BR (1) BR112014031278B1 (enExample)
CA (1) CA2875470C (enExample)
CY (1) CY1123337T1 (enExample)
DK (1) DK2861214T3 (enExample)
ES (1) ES2821502T3 (enExample)
HR (1) HRP20201761T1 (enExample)
HU (1) HUE051761T2 (enExample)
LT (1) LT2861214T (enExample)
PL (1) PL2861214T3 (enExample)
RS (1) RS60951B1 (enExample)
RU (1) RU2672106C2 (enExample)
SI (1) SI2861214T1 (enExample)
SM (1) SMT202000584T1 (enExample)
WO (1) WO2013186286A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2861214B1 (en) 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections
WO2015084677A1 (en) 2013-12-02 2015-06-11 Arytha Biosciences, Llc Toxoid preparation and uses thereof
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
CA3009119A1 (en) 2015-12-28 2017-07-06 Mb Biotech Ltd. Liposomes for treatment of an autoimmune disease
WO2017177073A1 (en) * 2016-04-07 2017-10-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use
DK3471732T3 (da) 2016-06-16 2020-08-17 Combioxin Sa Liposomer til behandling af virusinfektioner
ES3060425T3 (en) 2017-03-02 2026-03-26 Combioxin Sa Liposomes for inhibiting biofilm formation
US11344497B1 (en) * 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
KR102915698B1 (ko) * 2018-04-17 2026-01-28 콤비옥신 에스에이 폐렴의 치료
PT3781210T (pt) * 2018-04-20 2024-10-02 Combioxin Sa Tratamento da hipotensão com sépsis ou choque séptico
CN111214439B (zh) * 2018-11-23 2023-02-10 复旦大学 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途
EP4093458A4 (en) 2020-01-20 2024-01-17 Arytha Biosciences LLC Devices containing cellular membrane and uses thereof
JP2023536833A (ja) * 2020-07-31 2023-08-30 サインパス ファルマ，インク． サイトカイン放出及びサイトカインストームの抑制
CN115054577B (zh) * 2022-05-17 2024-06-21 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 纳米解毒剂及其在中和mrsa穿孔毒素的应用
WO2026099472A1 (en) 2024-11-08 2026-05-15 Universität Bern Liposomal compositions for treatment of inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
US20070122466A1 (en) * 2001-08-13 2007-05-31 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641247A (en) 1970-12-14 1972-02-08 Stanley Drug Products Inc Methods of treating bacterial infections
WO1991004019A1 (en) * 1989-09-12 1991-04-04 The Regents Of The University Of California Therapeutic peptides and proteins
NL9000207A (enExample) * 1990-01-29 1991-08-16 Duphar Int Res
WO1993004672A1 (en) * 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US6726925B1 (en) * 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US20050118250A1 (en) * 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
CA2368656A1 (en) * 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
JP4187249B2 (ja) 2002-03-08 2008-11-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 プレシナプス蛋白ｐ１２０
AU2003265241A1 (en) * 2002-05-23 2003-12-12 Activbiotics, Inc. Methods of treating bacterial infections and diseases associated therewith
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
WO2004087097A2 (en) * 2003-03-31 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US20090186073A1 (en) 2005-08-11 2009-07-23 National Institute Of Advanced Industrial Science And Technology Design of Delivery Vehicle Based On Rolling Model
CN1939340A (zh) * 2005-09-29 2007-04-04 中国人民解放军军事医学科学院毒物药物研究所 脂质体制剂
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US9637515B2 (en) * 2006-11-06 2017-05-02 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
CN1994279A (zh) * 2006-12-31 2007-07-11 西安力邦医药科技有限责任公司 注射用盐酸伊立替康脂质体的制备方法
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
CN101623262B (zh) * 2009-08-24 2011-02-02 海南美大制药有限公司 一种五水头孢唑啉钠前体脂质体制剂
WO2011160110A1 (en) * 2010-06-19 2011-12-22 Western University Of Health Sciences Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics
WO2012021107A2 (en) * 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
CN102327220B (zh) * 2011-07-14 2012-09-26 海南灵康制药有限公司 一种氯雷他定脂质体固体制剂
EP2861214B1 (en) 2012-06-14 2020-08-05 Universität Bern Tailored liposomes for the treatment of bacterial infections
US10716756B2 (en) 2016-06-20 2020-07-21 Vivacelle Bio, Inc. Compositions and methods for reducing reperfusion injury
ES3060425T3 (en) 2017-03-02 2026-03-26 Combioxin Sa Liposomes for inhibiting biofilm formation
KR102915698B1 (ko) 2018-04-17 2026-01-28 콤비옥신 에스에이 폐렴의 치료

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US20070122466A1 (en) * 2001-08-13 2007-05-31 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
WO2006052767A2 (en) * 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations

Also Published As

Publication number Publication date
US10744089B2 (en) 2020-08-18
RS60951B1 (sr) 2020-11-30
US20230031648A1 (en) 2023-02-02
JP6656321B2 (ja) 2020-03-04
BR112014031278B1 (pt) 2020-12-01
AU2013276565A1 (en) 2014-12-18
LT2861214T (lt) 2020-12-28
PL2861214T3 (pl) 2021-02-08
DK2861214T3 (da) 2020-10-12
EP3782606A1 (en) 2021-02-24
RU2018138012A (ru) 2019-03-21
CN104602672A (zh) 2015-05-06
JP6382801B2 (ja) 2018-08-29
CA2875470A1 (en) 2013-12-19
US20150157570A1 (en) 2015-06-11
US20220087934A1 (en) 2022-03-24
AU2019201776B2 (en) 2020-11-12
CA2875470C (en) 2021-01-12
US20200345639A1 (en) 2020-11-05
CN104602672B (zh) 2018-12-25
RU2014148284A (ru) 2016-08-10
HK1210018A1 (en) 2016-04-15
HRP20201761T1 (hr) 2020-12-25
SI2861214T1 (sl) 2021-01-29
ES2821502T3 (es) 2021-04-26
EP2861214B1 (en) 2020-08-05
EP2861214A1 (en) 2015-04-22
CN109549925B (zh) 2022-06-17
HUE051761T2 (hu) 2021-03-29
CN109549925A (zh) 2019-04-02
JP2018184470A (ja) 2018-11-22
JP2015519383A (ja) 2015-07-09
BR112014031278A2 (pt) 2017-06-27
SMT202000584T1 (it) 2020-11-10
RU2672106C2 (ru) 2018-11-12
CY1123337T1 (el) 2021-12-31
AU2019201776A1 (en) 2019-04-04
WO2013186286A1 (en) 2013-12-19
US12599558B2 (en) 2026-04-14

Similar Documents

Publication Publication Date Title
US12599558B2 (en) Tailored liposomes for the treatment of bacterial infections
US11007147B2 (en) Hydrogel toxin-absorbing or binding nanoparticles
Diab et al. Insights in nanoparticle-bacterium interactions: new frontiers to bypass bacterial resistance to antibiotics
JP2009536612A (ja) 脂質を用いた薬物製剤の高速送達とその処置方法
JP2017510662A (ja) 非結核性抗酸菌に対する活性を有するリポソームシプロフロキサシン製剤
US20200138710A1 (en) Compositions with permeation enhancers for drug delivery
CN101511430A (zh) 抗生素组合物
Selim et al. Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens
HK40046902A (en) Tailored liposomes for the treatment of bacterial infections
RU2780026C2 (ru) Специально разработанные липосомы для лечения бактериальных инфекций
KR102915698B1 (ko) 폐렴의 치료
HK1210018B (en) Tailored liposomes for the treatment of bacterial infections
US20210007985A1 (en) Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)